Issue link: https://www.e-digitaleditions.com/i/1138630
Tablets & Capsules July 2019 32M the public when the agency identi- fies ingredients that do not appear to be lawfully included in products marketed as dietary supplements. Ingredients are added to the list based on a preliminary assessment by the FDA, allowing the agency to communicate with the public while completing a final determination regarding these ingredients. DuPont partners with BioMe on smart capsule project COPENHAGEN, Denmark— DuPont Microbiome Venture, a divi- sion of DuPont Nutrition and Biosci- ences, has invested in UK-based startup BioMe Oxford, which is developing Biocapture, an oral smart capsule that can sample gut microbi- ota in both humans and animals. The technology is expected to provide new insights into how diets, ingredi- ents, and probiotics influence gut microbiota. DuPont will partner with BioMe Oxford and the University of Sheffield's Advanced Manufacturing Research Centre to further the devel- opment of the smart capsule. NICM receives grant to study new form of curcurmin SYDNEY, Australia—The Austra- lian government has awarded Western Sydney University's National Institute of Complementary Medicine Health Research Institute (NICM) an Innova- tion Connections grant to study the bioavailability of a new form of cur- cumin. NICM secured the $100,000 grant in partnership with Syd- ney-based Pharmako Biotechnologies and Australia's Department of Indus- try, Innovation, and Science. Cur- cumin is an anti-inflammatory derived from turmeric, but it is generally poorly water soluble, so it is not absorbed well in vivo. The project will study a new curcumin product developed by Pharmako Biotechnolo- gies called HydroCurc, which dis- perses well in water and is more read- ily absorbed in the body. The researchers will be determining whether the product successfully passes the blood-brain barrier, making it an effective therapy for managing chronic inflammation associated with degenerative and age-related diseases such as Alzheimer's and Parkinson's. DSM enters distribution agreement with SLS Nutraceuticals SINGAPORE—Royal DSM, a global health, nutrition, and sustain- able living company headquartered in Heerlen, Netherlands, has partnered with SLS Nutraceuticals, a subsidiary of Singapore-based Senescence Life Sciences, to distribute SLS's Edge, Revive, and NeuroShield products. The products combine western neu- roscience with eastern traditional medicine and are designed to opti- mize adult brain performance and support healthy brain aging. The dis- tribution agreement will initially focus on the Asia Pacific region, with potential future expansion. The com- panies will also collaborate on future clinical trials related to brain health and cognitive performance.